Endo announces agreement for paladin labs to develop, commercialize and supply quoin pharmaceuticals' qrx003 in canada

The product is under investigation for the treatment of netherton syndrome, a rare disease dublin , july 15, 2022 /prnewswire/ -- endo international plc (nasdaq: endp) announced today that its subsidiary endo ventures limited has entered into agreements with quoin pharmaceuticals inc. (nasdaq: qnrx) for the development, registration, supply, commercialization and distribution of qrx003 on an exclusive basis in canada. if the product is approved, paladin labs inc., an operating company of endo, will be responsible for all commercial activities in canada.
QNRX Ratings Summary
QNRX Quant Ranking